BUSINESS
Takeda’s ALK Drug Alunbrig Gets FDA’s Priority Status for Frontline NSCLC
Takeda Pharmaceutical has earned the FDA’s priority review status for its ALK inhibitor Alunbrig (brigatinib) for the first-line treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC), with the agency setting its target action date for June 23. The supplemental…
To read the full story
Related Article
BUSINESS
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





